Gan & Lee Insulin Glargine Target Type (2) Evaluating Research
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 567 participants.
Also called NCT03371108
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 567 participants
- Registry
-
NCT03371108
-
- Other papers using this trial's data
- Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT03371108. Randomized; no masking; primary purpose treatment. Start 2017-10-31 (actual); primary completion 2019-04-17 (actual). Results posted on 2022-03-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Gan & Lee Insulin Glargine Target Type (2) Evaluating Research
- Acronym
- GLITTER 2
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Biological)
- Gan & Lee Insulin Glargine Injection
- Intervention (Biological)
- Lantus®
- Lead sponsor
- Gan and Lee Pharmaceuticals, USA
Record details
- Record id
cardio:ct-nct03371108- Content hash
324ee12561a71a18a677417feeee2849684438c3eba1640d914e98b03681db1f